🔗 Share this article

As the United States proceeds with historic changes to its immunization guidelines, a particular individual has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about coronavirus vaccines in the pandemic and has zeroed in on possible deaths following Covid immunization in her recent time at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Immunization Program

Public health authorities were set to reveal sweeping revisions to the childhood vaccination calendar earlier this month, aligning the US with Denmark’s national calendar, according to reports – a significant shift that would put the US out of alignment with a large portion of the international standard with little proof for benefit. This reveal has been delayed until the coming year.

In place of Vinay Prasad, Dr. Høeg is set to speak at the gathering. She was newly appointed acting director of the FDA’s CDER, the fifth appointee to run the office this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a greater focus upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for halting specific pediatric immunization guidelines in the US to become more similar to the Danish model, a society with comprehensive healthcare and a number of inhabitants about the population of the state of Wisconsin.

So far comments, she has continued to focus on immunizations – traditionally the domain of Prasad, director of the FDA’s vaccine center – instead of pharmaceutical oversight.

Doubts Over Qualifications

The appointee has little discernible track record in medication creation, approval processes or management, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for overseeing the drug-regulation department, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She lacks experience in leading a sizeable institution. She has no expertise in industry regulation.”

Previous commissioners of the center would “be deeply familiar with legal statutes and the science of medication creation”, commented a former acting FDA commissioner. “Frankly, she doesn’t have the sort of resume that former directors who headed the center have had.”

The drug center has an enormous portfolio at the FDA, the former commissioner emphasized.

“Everybody just focuses on the new drug program, but the generic drug division clears a multitude of generic medications. There is also a biosimilars division, OTC medication office and more, and each of these need to be supervised,” Dr. Woodcock said. “The area you neglect, that is precisely what that I always told people is going to cause problems.”

Furthermore, a substantial management component to the role, which oversees more than 5,000 personnel. “It’s a massive administrative position, if you do it right,” she concluded.

Official Statement and Contentious Policies

In response to questions about Dr. Høeg's qualifications and whether this assignment signifies more teamwork among FDA leaders on vaccines, a representative said that the “concerns are based on incorrect assumptions”.

“Her resume matches the duties of her role,” the spokesperson explained, citing the months Høeg spent guiding the agency head on “medication safety and approval science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a controversial rapid medication authorization process that apparently worried her predecessors. “How are these therapies being chosen for this fast-track system? Who makes the choices?” Howard asked. “There is a lot of lack of transparency happening at the FDA right now.”

Overall, he stated, “the agency appears to be shifting towards laxer rules of pharmaceuticals, aside from immunizations.”

Documented Track Record on Immunizations

With vaccines, Dr. Høeg has a more documented, if troubling, history, some experts have noted. She authored a analysis using non-validated crowd-sourced reports to assess the frequency of myocarditis following Covid vaccination. She advised the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the incoming government featured revising regulations for novel immunizations and discontinuing “optional” vaccines, she stated post-election on a audio program. At the FDA, Dr. Høeg has according to sources floated the idea of excluding teenage boys from obtaining COVID-19 vaccinations.

“She’s an complete dogmatist who starts off with her beliefs and tailors the evidence to accommodate the data in a highly deceptive, fraudulent fashion,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Høeg aligned with other skeptics, {like|